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Intravascular Ultrasound Tissue Characterization
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Kenichi Tsujita, MD, PHD,* So-Yeon Choi, MD, PHD,* Osamu Katoh, MD,† Kenya Nasu, MD,†
Andreas Koenig, MD,‡ Michael Pieper, MD,§ Jason H. Rogers, MD, William Wijns, MD,¶
Dirk Böse, MD,# M. Pauliina Margolis, MD, PHD,** Jeffrey W. Moses, MD,* Gregg W. Stone, MD,*
Martin B. Leon, MD*
New York, New York; Aichi, Japan; Munich and Essen, Germany; Kreuzlingen, Switzerland;
Sacramento and San Diego, California; and Aalst, Belgium
Objectives We used virtual histology intravascular ultrasound (VH-IVUS) to investigate the natural history of coronary artery
lesion morphology.
Background Plaque stability is related to its histological composition.
Methods We performed serial (baseline and 12-month follow-up) VH-IVUS studies and examined 216 nonculprit lesions (plaque
burden 40%) in 99 patients. Lesions were classified into pathological intimal thickening (PIT), VH-IVUS–derived thin-
capped fibroatheroma (VH-TCFA), thick-capped fibroatheroma (ThCFA), fibrotic plaque, and fibrocalcific plaque.
Results At baseline, 20 lesions were VH-TCFAs; during follow-up, 15 (75%) VH-TCFAs “healed,” 13 became ThCFAs, 2
became fibrotic plaque, and 5 (25%) VH-TCFAs remained unchanged. Compared with VH-TCFAs that healed, VH-
TCFAs that remained VH-TCFAs located more proximally (values are median [interquartile range]) (16 mm [15 to
18 mm] vs. 31 mm [22 to 47 mm], p  0.013) and had larger lumen (9.1 mm2 [8.2 to 10.7 mm2] vs. 6.9 mm2
[6.0 to 8.2 mm2], p  0.021), vessel (18.7 mm2 [17.3 to 28.6 mm2] vs. 15.5 mm2 [13.3 to 16.6 mm2]; p 
0.010), and plaque (9.7 mm2 [9.6 to 15.7 mm2] vs. 8.4 mm2 [7 to 9.7 mm2], p  0.027) areas; however, base-
line VH-IVUS plaque composition did not differ between VH-TCFAs that healed and VH-TCFAs that remained VH-
TCFAs. Conversely, 12 new VH-TCFAs developed; 6 late-developing VH-TCFAs were PITs, and 6 were ThCFAs at
baseline. In addition, plaque area at minimum lumen sites increased significantly in PITs (7.8 mm2 [6.2 to 10.0
mm2] to 9.0 mm2 [6.5 to 12.0 mm2], p  0.001), VH-TCFAs (8.6 mm2 [7.3 to 9.9 mm2] to 9.5 mm2 [7.8 to 10.8
mm2], p  0.024), and ThCFAs (8.6 mm2 [6.8 to 10.2 mm2] to 8.8 mm2 [7.1 to 11.4 mm2], p  0.001) with a
corresponding decrease lumen areas, but not in fibrous or fibrocalcific plaque.
Conclusions Most VH-TCFAs healed during 12-month follow-up, whereas new VH-TCFAs also developed. PITs, VH-TCFAs, and
ThCFAs showed significant plaque progression compared with fibrous and fibrocalcific plaque. (J Am Coll
Cardiol 2010;55:1590–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.078p
H
D
r
D
a
cutopsy data suggest that plaque composition is a key deter-
inant of the propensity of atherosclerotic lesions to provoke
linical events (1). Fibroatheromas with a lipid-rich necrotic
ore (NC) and a thin fibrous cap (TCFA) seem particularly
rom the *Cardiovascular Research Foundation, New York, New York; †Toyohashi
eart Center, Aichi, Japan; ‡Ludwig Maximilian University, Munich, Germany;
Herzzentrum Bodensee, Kreuzlingen, Switzerland; University of California, Davis
edical Center, Sacramento, California; ¶OLV Hospital, Aalst, Belgium; #Univer-
ity of Duisburg-Essen, Essen, Germany; and the **Volcano Corporation, San Diego,
alifornia. Volcano Corporation (Rancho Cordova, California) has sponsored this
egistry. Dr. Kubo has received research grant support from Volcano Corporation. arone to rupture and result in coronary artery occlusion (2–6).
owever, our knowledge about the genesis, progression, and
See page 1598
r. Mintz is a member of the Speakers’ Bureau, serves as a consultant, has
eceived research/grant support, and is a stockholder with Volcano Corporation.
r. Rogers is a consultant for Volcano Corporation. Dr. Margolis is an employee
nd stockholder with Volcano Corporation. Drs. Stone and Leon serve as
onsultants for Volcano Corporation.Manuscript received April 8, 2009; revised manuscript received June 16, 2009,
ccepted July 14, 2009.
c
s
(
i
l
i
q
I
c
t
p
V
s
t
M
S
p
c
r
i
a
i
v
O
e
V
t
w
b
c
t
p

h

s

d
a
I
I
C
a
m
D
f
r
r
r
d
G
a
s
b
b
l
a
m
e
p
a
s
(
E
r
fi
a
i
(
a
t
f
V
w
c
g
g
r
a
V
u
D
e
o
(
T
(
(
p
V
fi
t
fi
u
w
c
m
t
c
N
S
f
t
C
q
t
a
p
t
1591JACC Vol. 55, No. 15, 2010 Kubo et al.
April 13, 2010:1590–7 Dynamic Nature of Coronary Plaque Morphologyharacterization of atherosclerosis is based mainly on cross-
ectional histopathological studies. Intravascular ultrasound
IVUS) is the gold standard for evaluation of coronary plaques
n vivo; however, conventional gray-scale IVUS has significant
imitations in assessing atheromatous plaque composition and
dentifying TCFAs. Spectral analysis of IVUS radiofre-
uency backscattered signals, known as virtual histology
VUS (VH-IVUS), was developed to improve IVUS tissue
haracterization and provide detailed quantitative informa-
ion on plaque composition in vivo (7). The aim of the
resent study was to use serial (baseline and follow-up)
H-IVUS to assess the natural history of coronary athero-
clerotic plaques, in particular, the development and evolu-
ion of TCFAs.
ethods
tudy population. Between August 2004 and July 2006, 990
atients at 42 centers were enrolled in a prospective, multi-
enter, nonrandomized, global VH-IVUS registry. From this
egistry, we identified 99 patients with serial VH-IVUS exam-
nations at baseline and follow-up for inclusion in the current
nalysis. Patients older than 18 years old without any contra-
ndication to IVUS imaging undergoing diagnostic or inter-
entional coronary procedures were enrolled in this study.
ther than age younger 18 years, there were no enrollment
xclusion criteria. Investigators were encouraged to repeat
H-IVUS imaging if the patient returned to the catheteriza-
ion laboratory for any reason; repeat cardiac catheterization
as performed routinely in 29 asymptomatic patients or
ecause of symptom recurrence in 72 patients. The ethics
ommittee at each participating institution approved the pro-
ocol, and written informed consent was obtained from all
atients. Lipid disorder was defined as total cholesterol level
200 mg/dl, low-density lipoprotein cholesterol 100 mg/dl,
igh-density lipoprotein cholesterol 50 mg/dl, triglycerides
150 mg/dl, or medication use. Hypertension was defined as
ystolic blood pressure 140 mm Hg, diastolic blood pressure
90 mm Hg, or use of an antihypertensive drug. Patients with
iabetes mellitus had a confirmed diagnosis or were using
ntidiabetic medications at study entry.
VUS image acquisition. A phased-array, 20-MHz, 3.2-F
VUS catheter (Eagle Eye, Volcano Corporation, Rancho
ordova, California) was placed into the distal coronary
rtery and pulled back to the aorto-ostial junction using a
otorized catheter pull-back system set at 0.5 mm/s.
uring pullback, gray-scale IVUS was recorded, raw radio-
requency data were captured at the top of the R wave, and
econstruction of the color-coded map by a VH-IVUS data
ecorder was performed (In-Vision Gold, Volcano Corpo-
ation). The gray-scale IVUS and captured radiofrequency
ata were written onto a CD-R or DVD-R, respectively.
ray-scale and VH-IVUS analyses. Off-line gray-scale
nd VH-IVUS analyses were performed by pcVH 2.1
oftware (Volcano Corporation). Corresponding images of
aseline and follow-up IVUS examinations were identified ey the distance from 2 fiduciary
andmarks such as side branches
nd stent edges. Gray-scale IVUS
easurements of lumen, external
lastic membrane (EEM), and
laque and media (P&M, defined
s EEM minus lumen) cross-
ectional areas and plaque burden
defined as P&M divided by
EM) were performed for every
ecorded frame (8). We identi-
ed nonculprit, untreated lesions
s having a plaque burden 40%
n at least 3 consecutive frames
1.5 mm in length). VH-IVUS
nalysis of these nonculprit, un-
reated lesions was also performed
or every recorded frame. The 4
H-IVUS plaque components
ere color-coded as white (dense
alcium [DC]), red (NC), light
reen (fibrofatty [FF]), and dark
reen (fibrotic tissue [FT]) and
eported as percentages of plaque
rea and total plaque volume (7).
olumetric gray-scale and VH-IVUS analyses were performed
sing Simpson’s rule.
efinition of lesion types. Lesions were classified by 2
xperienced, independent observers (T.K. and A.M.) based
n plaque composition: pathological intimal thickening
PIT), virtual histology intravascular ultrasound–derived
CFA (VH-TCFA), thick-capped fibroatheroma
ThCFA), fibrotic plaque, and fibrocalcific plaque (9,10)
Fig. 1). PIT consisted of mainly a mixture of FT and FF
laque with 10% confluent NC and 10% confluent DC.
H-TCFA was a fibroatheroma without evidence of a
brous cap: 10% confluent NC with 30° NC abutting
he lumen in at least 3 consecutive frames. ThCFA was a
broatheroma (10% of confluent NC in at least 3 consec-
tive frames) with a definable fibrous cap. Fibroatheromas
ith features of both VH-TCFAs and ThCFAs were
lassified as VH-TCFAs. Fibrotic plaque consisted of
ainly fibrous tissue with 10% confluent NC, 15% FF
issue, and 10% confluent DC. Fibrocalcific plaque was
omposed of nearly all FT and DC with 10% confluent
C.
tatistical analysis. Categorical variables were presented as
requencies, with comparison using chi-square statistics or
he Fisher exact test (if there was an expected cell value5).
ontinuous variables were presented as medians and inter-
uartile ranges and were compared using Mann-Whitney U
est or the Wilcoxon signed rank test. The changes in lumen
nd P&M area during follow-up were compared among 5
laque types by Kruskal-Wallis analysis using Steel-Dwass
est for multiple comparisons. A p value 0.05 was consid-
Abbreviations
and Acronyms
DC  dense calcium
EEM  external elastic
membrane
FF  fibrofatty
FT  fibrotic tissue
IVUS  intravascular
ultrasound
NC  necrotic core
PIT  pathological intimal
thickening
P&M  plaque and media
TCFA  thin-capped
fibroatheroma
ThCFA  thick-capped
fibroatheroma
VH-IVUS  virtual histology
intravascular ultrasound
VH-TCFA  virtual histology
intravascular ultrasound–
derived thin-capped
fibroatheromared statistically significant. Intraobserver variability and
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Dynamic Nature of Coronary Plaque Morphology April 13, 2010:1590–7nterobserver variability for lesion type classifications were
easured by  test of concordance using the data without
orrection for correlated observations within individuals.
esults
atient and lesion characteristics. Baseline patient char-
cteristics are listed in Table 1. The follow-up period was 12
interquartile range [IQR] 7 to 14) months. Systolic blood
ressure (136 mm Hg [IQR 120 to 160 mm Hg] to 135 mm
g [IQR 120 to 148 mm Hg], p  0.005) and diastolic
lood pressure (80 mm Hg [IQR 72 to 82 mm Hg] to 78
m Hg [IQR 68 to 80 mm Hg], p  0.011) decreased
ignificantly during follow-up. There were no significant
ifferences in the serum levels of total cholesterol (193
Figure 1 Plaque Classification by VH-IVUS
(A) Pathological intimal thickening. (B) Virtual histology intravascular ultrasound (V
thin-capped fibroatheroma. (C) Thick-capped fibroatheroma. (D) Fibrotic plaque. (E
linical Patient Characteristicst Baseline a d Follow-upTable 1 Clinica Pa ient Characteristicsat Baseline and Follow-up
Baseline Follow-up
Age, yrs 66 (55–73) 67 (56–74)
Male sex 78 78
Clinical presentation
ACS/none-ACS 23/77 0/100
Target coronary vessel
LAD/LCX/RCA 54/20/26 54/20/26
Previous MI 43 46
Coronary risk factors
Hypertension 72 72
Diabetes 31 31
Lipid disorder 71 74
Smoker 55 58
Family history of CAD 43 43
Medications
Antiplatelet agent 85 96
Beta-blocker 51 49
ACEI/ARB 30 42
Calcium-channel blocker 31 30
Insulin 7 7
Statin 53 69
alues are given as median and interquartile range or %.
ACEI  angiotensin-converting enzyme inhibitor; ACS  acute coronary syndrome; ARB a
ngiotensin receptor blocker; CAD  coronary artery disease; LAD  left anterior descending;
CX  left circumflex; RCA  right coronary artery.g/dl [162 to 221 mg/dl] to 187 mg/dl [IQR 164 to 213
g/dl], p  0.2), low-density lipoprotein cholesterol (111
g/dl [IQR 88 to 132 mg/dl] to 103 mg/dl [IQR 85 to 127
g/dl], p  0.1), and high-density lipoprotein cholesterol
47 mg/dl [IQR 37 to 58 mg/dl] to 49 mg/dl [IQR 40 to 57
g/dl], p  0.1) between baseline and follow-up. Overall,
16 nonculprit, untreated lesions were identified, analyzed
y gray-scale and VH-IVUS, and classified as PIT (n 62),
H-TCFA (n  20), ThCFA (n  93), fibrous plaque
n  22), and fibrocalcific plaque (n  19), as shown in
able 2. Intraobserver and interobserver variability yielded
ood concordance for lesion type classifications (  0.90
nd   0.87, respectively).
erial gray-scale IVUS analysis. The P&M area at the
inimum lumen site increased significantly during
ollow-up in PITs (7.8 mm2 [IQR 6.2 to 10.0 mm2] to 9.0
m2 [IQR 6.5 to 12.0 mm2], p 0.001), VH-TCFAs (8.6
m2 [IQR 7.3 to 9.9 mm2] to 9.5 mm2 [IQR 7.8 to 10.8
m2], p 0.024), and ThCFAs (8.6 mm2 [IQR 6.8 to 10.2
m2] to 8.8 mm2 [IQR 7.1 to 11.4 mm2], p  0.001), but
ot in fibrotic or fibrocalcific plaque. The increase in P&M
rea was significantly greater in PITs, VH-TCFAs, and
hCFAs compared with fibrocalcific plaque (Fig. 2). Cor-
espondingly, the minimum lumen area decreased signifi-
antly in PITs (8.2 mm2 [IQR 6.3 to 10.5 mm2] to 7.2 mm2
IQR 5.2 to 9.6 mm2], p  0.001), VH-TCFAs (7.2 mm2
IQR 6.2 to 9.0 mm2] to 6.8 mm2 [IQR 5.6 to 8.3 mm2],
 0.005), and ThCFAs (6.8 mm2 [IQR 5.3 to 8.4 mm2]
o 6.4 mm2 [IQR 4.4 to 8.5 mm2], p  0.001), but not in
brotic or fibrocalcific plaque. The decrease in minimum
umen area was significantly greater in PITs compared with
hCFAs, fibrotic plaque, and fibrocalcific plaque (Fig. 2).
erial VH-IVUS analysis. During follow-up, the percent-
ge of NC area at the minimum lumen site increased
ignificantly in PITs (8% [IQR 4% to 12%] to 11% [IQR
% to 21%], p  0.008), but decreased significantly in
H-TCFAs (32% [IQR 23% to 36%] to 21% [IQR 15% to
4%], p  0.001) and ThCFAs (22% [IQR 17% to 28%] to
0% [IQR 15% to 26%], p 0.043). The percentage of NC
)–derived
calcific plaque.H-IVUS
) Fibrorea in fibrotic plaque and fibrocalcific plaque did not
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April 13, 2010:1590–7 Dynamic Nature of Coronary Plaque Morphologyhange between baseline and follow-up. Volumetric VH-
VUS analysis supported these observations. Data are
hown in Table 2.
volution of nonculprit coronary lesions. At baseline,
here were 20 VH-TCFAs. During follow-up, 15 (75%)
H-TCFAs healed by evolving into a different lesion type,
3 became ThCFAs, and 2 became fibrotic plaques,
hereas 5 (25%) VH-TCFAs remained unchanged (Fig. 3).
ompared with VH-TCFAs that healed, VH-TCFAs that
emained unchanged located more proximally (distance
rom coronary ostium to the lesion of 16 mm [IQR 15 to 18
m] vs. 31 mm [IQR 22 to 47 mm], respectively, p 
.013) and had larger lumen areas (9.1 mm2 [IQR 8.2 to
0.7 mm2] vs. 6.9 mm2 [IQR 6.0 to 8.2 mm2], p  0.021),
EM areas (18.7 mm2 [IQR 17.3 to 28.6 mm2] vs. 15.5
m2 [IQR 13.3 to 16.6 mm2], p  0.010), and P&M areas
9.7 mm2 [IQR 9.6 to 15.7 mm2] vs. 8.4 mm2 [IQR 7.2 to
.7 mm2], p  0.027); however, baseline VH-IVUS plaque
omposition was not different between VH-TCFAs that
ealed versus VH-TCFAs that remained unchanged. Heal-
ng of VH-TCFAs was not related to acute coronary
resentations at baseline (p 0.3), follow-up duration (p
.7), angiotensin-converting enzyme inhibitor/angiotensin
eceptor blocker administration (p  0.2), statin adminis-
ration (p  0.2), or change in serum low-density lipopro-
ein levels during follow-up (p  0.9).
During follow-up, 12 new VH-TCFAs developed; 6 new
H-TCFAs were PIT and 6 were ThCFAs at baseline.
here was no difference in baseline characteristics between
ITs that evolved into VH-TCFAs compared with PITs
hat did not develop into VH-TCFAs. Although the
ercentage of NC area at baseline was not different between
hCFAs that evolved into VH-TCFAs compared with
hCFAs that did not developed into VH-TCFAs, the
ercentage of DC area (4% [IQR 2% to 5%] vs. 11% [IQR
% to 20%], p  0.006) was significantly lower in ThCFAs
hat evolved into VH-TCFAs. During the follow-up pe-
iod, no lesions resulted in acute coronary events, including
he 12 “new” VH-TCFAs. Representative serial IVUS
mages at baseline and follow-up are shown in Figure 4.
iscussion
his is the first report to use serial VH-IVUS to assess the
atural history of coronary artery lesion morphology in vivo.
he major findings of our analysis are as follows. 1) Most
H-TCFAs stabilized or healed during 12 months of
ollow-up. Only proximal VH-TCFAs in larger vessels with
ore plaque appeared to heal less often. 2) New VH-
CFAs developed from PITs or ThCFAs. 3) Lesions
lassified as PIT, VH-TCFA, and ThCFA showed signif-
cant progression (increase plaque and decrease in lumen)
ompared with fibrotic and fibrocalcific plaque.
istological classification of atherosclerotic plaque.
ased on histological composition and structure, the Amer-ican Heart Association’s Committee on Vascular LesionsCh T
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Dynamic Nature of Coronary Plaque Morphology April 13, 2010:1590–7ecommended a practical classification of human atheroscle-
otic lesions that provided a basis for understanding changes
n progression, stabilization, or regression of atherosclerotic
Figure 2 Changes in P&M Area and Lumen Area During Follow-
The increase of plaque and media (P&M) area and the decrease in minimum lume
classified as pathologic intimal thickening (PIT) compared with fibrotic or fibrocalcifi
thin-capped fibroatheroma.
Figure 3 Changes in Plaque Characteristics Assessed
by VH-IVUS Between Baseline and Follow-Up
During follow-up, 75% of VH-TCFAs evolved into ThCFA or fibrotic plaque and
25% remain unchanged. Conversely, 10% of PITs and 6% of ThCFAs evolved
into VH-TCFAs. No fibrotic plaque and fibrocalcific plaque evolved into fibroathe-
romas. Abbreviations as in Figures 1 and 2.aesions (1). Virmani et al. (4) proposed TCFA as a specific
esion type that was a precursor of plaque rupture. Subsequent
tudies defined TCFA fibrous cap thickness as 65 m (2)
nd showed that nearly 75% of TCFAs had 10% of the
laque area occupied by a lipid-rich NC (3). Atherosclerotic
esions were subsequently classified into intimal xanthoma,
ntimal thickening, PIT, fibrous cap atheroma, TCFA,
alcified nodule, and fibrocalcific plaque (4). Based on
ost-mortem histology data, this specific lesion classifica-
ion allowed correlation with morphology determined by
linically applicable diagnostic measurements including
ewer in vivo imaging techniques such as VH-IVUS.
Tissue characterization by VH-IVUS is a potential tool
o enable an accurate evaluation of the coronary plaque
omposition. Nair et al. (7), in a histological study, reported
hat VH-IVUS had an 80% to 92% accuracy for identifica-
ion of coronary plaque DC, NC, FF, or FT. Subsequent
tudies demonstrated the high reproducibility of VH-IVUS
nalyses (11,12). Hartmann et al. (12) showed that the
elative difference of volumetric VH-IVUS analysis in re-
eated pull-backs was 1% for NC and 3% for DC, FF,
nd FT. These studies formed the backbone of the current
erial VH-IVUS analysis. In the present VH-IVUS study,
oronary lesions were classified as PIT, VH-TCFA, ThCFA,
brotic plaque, and fibrocalcific plaques, similar to the
istopathological classification. Presumably, this VH-IVUS
lassification also represented the different stages of devel-
pment of atherosclerosis from early intimal thickening to
ulnerable lesions (such as VH-TCFA) to stable fibrocal-
ific disease.
H-TCFAs. Using VH-IVUS in a small number of pa-
ients, Rodriguez-Granillo et al. (9) reported that VH-
CFAs were detected 3 times as often in secondary,
onobstructive lesions of acute coronary syndrome patients
ompared with stable angina patients. In a larger VH-IVUS
nalysis. Hong et al. (13) reported that primary lesions of
significantly different among lesion phenotypes and were greater in lesions
ons. ThCFA  thick-capped fibroatheroma; VH-TCFA  virtual histology–derivedUp
n were
c lesicute coronary syndrome patients more often contained
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April 13, 2010:1590–7 Dynamic Nature of Coronary Plaque MorphologyH-TCFAs (as well as already ruptured plaques) than those
f stable angina patients (89% vs. 62%, p  0.001).
urthermore, in a 3-vessel VH-IVUS analysis, they dem-
nstrated that the overall frequency of VH-TCFAs was 2.5
er patient with acute coronary syndrome versus 1.7 per
atient with stable angina (p  0.001) (14). However, none
f these studies examined that natural history of this lesion
ubset.
atural history of TCFAs. There are various possible
athways in the evolution and stabilization of TCFAs.
ccording to pathologic studies, TCFAs are precursor
esions for plaque rupture. The thin, fibrous cap is distin-
uished by the loss of smooth muscle cells, extracellular
atrix, and inflammatory infiltrate. In a series of 200
udden death cases, approximately 60% of acute thrombi
Figure 4 Representative Images of Serial Intravascular Ultraso
(A) VH-TCFAs became ThCFAs. (B) VH-TCFAs became fibrous plaques. (C) VH-TCFA
contact with the lumen shifted axially (arrows). (D) PITs became VH-TCFAs. (E) Thesulted from rupture of a TCFA (4). Other relevant leatures that contribute to plaque rupture include the extent
f inflammation in the fibrous cap, fissuring, calcification,
ntraplaque vasa vasorum, and intraplaque hemorrhage.
However, not all TCFAs rupture, although the mecha-
ism of healing of TCFAs is not well established. The
ransformation of hematoma and/or thrombus into fibro-
uscular tissue and the formation or increase in thickness of
he fibrous cap could lead to plaque stabilization (1).
irmani et al. (3) and Burke et al. (5) proposed that a silent
laque rupture or a plaque rupture proximal to a lesion
ight lead to mural thrombus and subsequent formation of
fibrotic cap over the TCFA. Moreover, many animal and
linical studies have shown that changes in the plaque
nvironment, such as a reduction in plasma lipid concen-
rations, can stabilize and cause regression of even advanced
t Baseline and Follow-Up
ained unchanged, although the location of the necrotic core in
ecame VH-TCFAs. Abbreviations as in Figures 1 and 2.und a
s rem
CFAs besions (15). The American Heart Association recommen-
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Dynamic Nature of Coronary Plaque Morphology April 13, 2010:1590–7ation suggests that fibroatheromas may become fibrocal-
ific lesions without developing complex features such as
urface defects, hematoma/hemorrhage, and/or thrombosis
1). In the present VH-IVUS study, most (75%) VH-
CFAs healed or stabilized to become ThCFAs or fibrotic
laques, and new VH-TCFAs developed from PITs and
hCFAs during 12 months of follow-up. Furthermore, no
esions resulted in plaque rupture or caused acute events,
ncluding “new” VH-TCFAs. Previous IVUS studies
howed that plaque rupture itself does not necessarily cause
cute events unless there is thrombus formation with sig-
ificant lumen compromise (16). However, the current
opulation of VH-TCFAs had little lumen compromise,
nd this might have contributed to a lack of clinical events.
Coronary artery TCFAs occur in a limited, focal distri-
ution as do plaque ruptures and acute occlusions. Cheruvu
t al. (6) longitudinally sectioned coronary arteries to show
hat TCFAs clustered in the proximal coronary arteries;
0% of TCFAs were present within the first 22 mm and
0% within the first 33 mm of the left anterior descending
nd left circumflex arteries, and 50% of TCFAs were
bserved within the first 31 mm and 90% within the first 74
m of the right coronary artery. In an angiographic study,
ang et al. (17) showed that acute coronary occlusions
eading to ST-segment elevation myocardial infarction
ended to cluster in predictable “hot spots” within the
roximal third of the coronary arteries. Hong et al. (18)
erformed 3-vessel gray-scale IVUS to demonstrate that
laque ruptures occur mainly in proximal segments (83%) of
he left anterior descending artery, the proximal (48%) and
istal (32%) segments of the right coronary artery, and the
ntire left circumflex artery. Using VH-IVUS, Valgimigli et
l. (19) confirmed that plaque composition had a nonuni-
orm distribution, with proximal segments having a signif-
cantly larger NC compared with distal segments (mean
3% vs. 8.7%, p  0.05). Moreover, VH-TCFAs were more
ommon in proximal coronary artery segments compared with
istal segments (9). The present study extends these observa-
ions to show that proximal VH-TCFAs in larger vessels with
ore plaque seemed to heal less often compared with distal
H-TCFAs and that this might contribute to plaque rupture
nd subsequent thrombosis.
H-IVUS assessment of the natural history of coronary
rtery disease. Identification of coronary lesions at signif-
cant risk of plaque progression is of great clinical impor-
ance. Post-mortem studies have clearly shown that subclin-
cal and repeated plaque rupture followed by healing have a
ey role in plaque progression (5). Younger patient age,
nstable clinical presentation, and overall severity of angio-
raphic coronary artery disease have been proposed as
redictors of rapid coronary stenosis progression (20). In a
erial angiographic study, Kaski et al. (21) showed that
ean stenosis diameter reduction was significantly greater
n complex lesions than in smooth lesions (11.6% vs. 3.9%
hange; p 0.001). In a serial gray-scale IVUS study, Berry
t al. (22) demonstrated that patients with angiographic firogression had greater plaque volume at baseline on IVUS
p  0.0495) and a significantly greater increase in plaque
olume from baseline to follow-up (p  0.0283) compared
ith patients with no angiographic progression. The
resent study extends these previous observations by
emonstrating varying degrees of plaque progression
mong the 5 VH-IVUS lesion subtypes. Lesions classi-
ed as PIT, VH-TCFA, and ThCFA showed significant
rogression (increase in plaque mass and decrease in
umen area) compared with fibrotic and fibrocalcific
laque in which there were no geometric changes during
2 months of follow-up.
The IBIS-1 (Integrated Biomarker and Imaging
tudy-1) substudy assessed the correlation between tem-
oral changes in plaque composition and circulating
iomarkers (23). Subsequently, the IBIS-2 study demon-
trated that lipoprotein-associated phospholipase A2 in-
ibition prevented NC growth within coronary athero-
clerotic plaques (24). The PROSPECT (Providing
egional Observation to Study Predictors of Events in
he Coronary Tree) trial was designed to use VH-IVUS
o detect high-risk, rupture-prone lesions. The SPE-
IAL (Study of Prospective Events in Coronary Inter-
ediate Atherosclerotic Lesions) was designed to corre-
ate lesion characteristics, patient risk factors, and other
easurements with subsequent cardiac events as well as
laque progression and regression. VH-IVUS may pro-
ide critical new information about the role of vulnerable
laque and about the natural progression of coronary
rtery disease.
tudy limitations. First, this was a registry study and not
epresentative of the whole spectrum of patients with
oronary heart disease with follow-up at the discretion of
he investigators. Larger serial VH-IVUS studies with
onger term follow-up may help to distinguish plaques
rone to rupture and, as a consequence, to lead to cardiac
vents. Second, the present study evaluated only noncul-
rit lesions with modest plaque burden that were not
ccompanied by significant lumen narrowing. Third, the
xial resolution of VH-IVUS (100 to 200 m) was
nadequate to detect critical fibrous cap thickness, cur-
ently defined as 65 m. Finally, the limited longitu-
inal resolution of VH-IVUS imaging, based on
lectrocardiography-triggered cross-sectional analysis,
ay have biased the identification of corresponding
mages in serial (baseline and follow-up) VH-IVUS
tudies.
onclusions
laque stability is related to its histological composition.
lthough most VH-TCFAs seem to stabilize or heal during
ollow-up, proximal VH-TCFAs in larger vessels with more
laque appear to heal less often. Moreover, new VH-
CFAs can develop from PIT or ThCFA. Lesions classi-
ed as PIT, VH-TCFA, and ThCFA showed significant
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April 13, 2010:1590–7 Dynamic Nature of Coronary Plaque Morphologylaque progression compared with fibrous and fibrocalcific
laque. In comparison with other clinically available,
atheter-based, intracoronary diagnostic tools, VH-IVUS
ay be useful in assessing the natural history of stable and
nstable atherosclerotic lesions.
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